Revised Prices of Anti-Cancer Medicines to Come into Effect from 9th November;

1. At a Glance

• NPPA has capped trade margins at 30% on 137 non-scheduled anti-cancer drugs using the Trade Margin Rationalisation (TMR) approach. The revised MRPs apply from 9 November 2026 [1][2].
• TMR caps the margin added along the supply chain, from the price at which a drug leaves the manufacturer or distributor up to the MRP. It does not regulate the manufacturer's own price, which makes it the main tool for drugs outside Schedule-I of DPCO 2013 [1].
• Consumers are estimated to save ₹3,502.31 crore a year. MRPs fell for 1,031 formulations, 600 of them by more than 50%, with the largest cut at 96.45% [1].
• UPSC relevance: the measure brings together health equity (GS-II), drug pricing and industrial regulation (GS-III), and the split of work between the Centre and the states in enforcement.

2. Why in the News

• 17 October 2026: NPPA issued Notification S.O. 5690(E), which gives effect to TMR for anti-cancer drugs. It stays in force "until further orders" [1].
• NPPA published revised MRPs for 543 brands of anti-cancer medicines, effective 9 November 2026. The list is to be updated continually as manufacturers submit revised prices [2].
• The cap covers immunotherapy medicines for more than 20 cancer types and biologics such as Denosumab, Pegfilgrastim and Bevacizumab [2].

3. Background & Evolution

• 29 August 1997: NPPA was created by a Government of India Resolution (Gazette of India No. 159). It is an attached office of the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers [9].
• 4 September 1997: The Union delegated to NPPA the powers to fix, implement, monitor and enforce prices of scheduled bulk drugs and formulations [9].
• 7 December 2012: The National Pharmaceutical Pricing Policy (NPPP), 2012 was notified. DPCO 2013 was issued under it [6][7].
• Pharma Sahi Daam mobile app launched to let consumers check medicine prices [11].
• February 2019 (pilot TMR): 42 non-scheduled anti-cancer drugs were brought under a 30% trade margin cap. MRPs of 526 brands fell by up to 90%, an estimated saving of about ₹984 crore a year [3].
• An earlier PIB release reported MRPs of 390 anti-cancer non-scheduled medicines reduced by up to 87% [4].
• 29 August 2022 (25th Foundation Day): IPDMS 2.0 (Integrated Pharmaceutical Database Management System) was launched [10].
• August 2026: A Parliamentary Standing Committee noted that there is no set timeframe for building a permanent TMR framework into DPCO 2013 [5].
• October 2026: TMR expanded from 42 to 137 anti-cancer drugs [1].

4. Core Static Facts

5. Multi-Dimensional Analysis

Economic

• Saves an estimated ₹3,502.31 crore a year, about 3.5 times the ₹984 crore from the 2019 pilot [1][3].
• Manufacturer prices are untouched, so innovation and supply incentives are less distorted than under ceiling prices. The cost falls mainly on distribution margins [1].
• Because the 30% cap is tied to Para 20(1), later annual price increases cannot erode the relief [1].

Social / Health equity

• Cancer care involves high out-of-pocket expenditure (OOPE). Cuts of more than 50% on 600 formulations directly reduce the financial burden of treatment [1].
• Including immunotherapies and biologics makes newer treatments more affordable, not just older chemotherapy drugs [2].

Legal / Regulatory

• TMR fills the gap left by Schedule-I, which covers only NLEM drugs [6].
• There is still no permanent TMR framework in DPCO 2013. TMR currently runs through case-by-case notifications [5].
• Cancer drugs not yet launched are covered in advance, which stops launch prices from being set high to begin with [1].

Administrative / Federal

• The Centre (NPPA) sets the rules, the states (State Drug Controllers) enforce them, and consumers report violations through the app [1][12].
• The continually updated brand list (543 brands so far) shows that compliance depends on manufacturers submitting revised price lists [2].

Governance / Ethical

• The decision followed a process: the health ministry provided expert input (DGHS committee) and the pricing authority acted on it, which improves technical legitimacy [1].
• Making MRP display mandatory, including on websites, improves transparency for patients [1].

6. Recent Developments (last 12–18 months)

• 1 December 2025: Ceiling prices stand fixed for 935 scheduled formulations [7].
• 2025–26: The Pharma Jan Samadhan portal was integrated with Pharma Sahi Daam [12].
• August 2026: Standing Committee observed that there is no timeline for a permanent TMR framework [5].
• 17 October 2026: S.O. 5690(E) issued, bringing 137 anti-cancer drugs under the 30% trade margin cap [1].
• Late October / early November 2026: Revised MRPs for 543 brands published [2].
• 9 November 2026: Revised prices take effect [1][2].

7. Prelims Hooks

• NPPA works under the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers (not MoHFW) [1][9].
• NPPA was set up on 29 August 1997 by a Government Resolution, not by an Act of Parliament [9].
• The 2026 TMR covers 137 non-scheduled anti-cancer drugs [1].
• The maximum permissible trade margin under this TMR is 30% [1].
• The enabling notification is S.O. 5690(E), dated 17 October 2026 [1].
• Para 20(1) of DPCO 2013 allows an annual price increase for non-scheduled drugs, subject to the 30% margin cap [1].
• Estimated annual consumer savings: ₹3,502.31 crore [1].
• Highest MRP reduction reported: 96.45% [1].
• 10–15 of the 137 drugs are not yet launched in India but are pre-covered [1].
• The expert committee was constituted by DGHS (MoHFW) [1].
• The first anti-cancer TMR (2019) covered 42 drugs and 526 brands, with cuts of up to 90% [3].
• NLEM is published by MoHFW and notified as the First Schedule of DPCO 2013 [6].
• Ceiling prices of scheduled drugs are revised annually by WPI (All Commodities), by 1 April [7].
• Pharma Sahi Daam is NPPA's consumer app for checking prices and reporting violations [1][11].

8. What the ₹3,502 Crore Saving Does Not Tell You

• A 96% cut shows the old MRP was the problem, not the medicine's cost
• The new cap allows only 30% trade margin, yet one MRP fell by 96.45% [1].
• For that to happen, the old MRP must have been about 28 times the new one. Almost all of that gap was margin added after the drug left the company.

• So the cut removes inflated MRPs. It does not show that cancer treatment has become cheap.

• The saving is worked out on MRP, but many patients never paid full MRP

• The ₹3,502.31 crore figure is an estimate built from MRP cuts [1].

• Patients who already got discounts, or got drugs free in public hospitals, save less than the headline suggests. The real gain goes mainly to those who paid full MRP at private counters.

• Medicines are only one part of a cancer bill

• The Parliamentary Standing Committee on Health says 70–80% of cancer treatment cost in India is paid out of pocket, at an average of about ₹7.5 lakh per patient [13].
• It also says spending on medicines is the biggest part of catastrophic out-of-pocket spending (health spending so high that it pushes a family into debt or poverty) [13].

• A margin cap lowers the medicine part. It does nothing for surgery, radiation, tests, travel or lost income.

• For new, patented drugs, the costly part is untouched

• TMR leaves the manufacturer's own price alone [1].

• For immunotherapies and biologics such as Bevacizumab [2], most of the price is the company's price, not the trade margin. A 30% cap on a very costly drug still leaves a very costly drug.

• Drugs left off the list can only stop their prices rising. Their starting price stays as it is

• Other non-scheduled anti-cancer drugs only have a rule that their MRP cannot go up by more than 10% in 12 months [17].
• That limits how fast a price grows. It does not bring down a price that was already too high.

9. Why the Cap Stands on Temporary Legal Ground

• TMR depends on emergency powers, not a standing rule
• The 2019 pilot used NPPA's extraordinary powers under Para 19 of DPCO 2013, meant for unusual situations in the public interest [16].
• The 2026 notification likewise stays in force only "until further orders" [1].

• So each expansion is a one-off order. A later order can withdraw it, and a court can be asked to examine each one.

• Seven years on, the pilot is still a pilot

• The 42-drug cap began in 2019 [3]. In August 2026 the Standing Committee found there is still no set timeframe for building a permanent TMR framework into DPCO 2013 [5].

• The 2026 move makes the pilot bigger (42 to 137 drugs) without giving it a permanent legal base.

• The regulator itself has no statute behind it

• NPPA was created by a Government Resolution in 1997, not by an Act of Parliament [9].
• A body without its own law, using emergency powers, is easier for companies to challenge in court than a regulator with clear statutory powers.

10. Why a Price Cap Is Only as Strong as Its Recovery

• Most overcharging money is never collected
• When a company sells above the allowed price, NPPA sends a demand to recover the extra amount.
• As of 2025, ₹8,526 crore (85% of all such demands) was still unrecovered [5].

• About 70% of that is stuck in court cases, some pending for more than 20 years [5].

• This is an old problem that has not been fixed

• In 2012–13, a Standing Committee found NPPA had recovered only ₹233.99 crore out of ₹2,577.44 crore demanded [18].

• It recommended arbitration (settling disputes outside court) to cut litigation [18]. The backlog has grown since.

• Why this matters for the 137 drugs

• A company that overcharges can go to court and keep the money while the case drags on. So the cap only works if companies obey it from the start.
• The checking on the ground is done by State Drug Controllers [1], and the list keeps changing as companies send in new prices [2]. If recovery is weak, the rule has little to stop a company that ignores it.

11. Why One Flat 30% Rate Is Not Enough

• The same percentage means very different money
• A 30% margin on a ₹100 tablet is ₹30. On a ₹1 lakh biologic it is ₹30,000, for roughly the same work of storing and selling it.

• So a flat cap still leaves the largest rupee margins on the costliest cancer drugs.

• WHO suggests a sliding scale instead

• WHO's guidance on pharmaceutical pricing suggests a regressive mark-up: the allowed percentage falls as the drug's price rises [15].

• WHO's 2020 guideline also suggests publishing prices at each step of the supply chain [14].

• Parliament thinks margins are still too high

• The Standing Committee on Health says retail margins on anti-cancer drugs are still 50–60% [13].
• It notes that the average markup on common non-scheduled medicines is about 43% [13].
• It wants stricter TMR across all anti-cancer molecules, not a chosen list [13]. A list of 137 leaves room for companies to move sales to drugs that are not on it.

12. What Should Follow, and Who Must Act

• Department of Pharmaceuticals: write TMR into DPCO 2013, with a deadline
• The Standing Committee asked for a permanent TMR framework to be finalised within a set timeline [5].

• A standing rule would replace repeated use of emergency powers under Para 19 [16].

• NPPA: fix the recovery system first

• The Committee recommended a fast-track dispute resolution mechanism for cases not in court, and a dedicated legal cell in NPPA for long-pending court cases [5].

• NPPA: move to slabs and widen the list

• Use a lower margin percentage for costlier drugs, as WHO suggests [15].

• Cover all anti-cancer molecules, as the Health Committee recommends [13].

• NPPA and State Drug Controllers: track whether drugs stay on the shelves

• WHO advises monitoring how pricing policy affects price, availability and affordability [14].

• If a margin is too low for a costly, cold-stored drug, sellers may stop stocking it. Regular stock checks would catch this early.

• Union health ministry: pair price caps with insurance

• The Health Committee sees health insurance as a pre-payment and risk-pooling tool (people pay small amounts in advance, so no single family bears the full cost) for cancer care [13].
• A margin cap lowers the bill. Insurance decides who pays the part that remains.

13. Anchors for Answers

• Data: 70–80% of cancer treatment cost is paid out of pocket; average about ₹7.5 lakh per patient [13]
• Data: ₹8,526 crore (85%) of overcharging demands unrecovered as of 2025; about 70% stuck in litigation [5]
• Data: Retail margins on anti-cancer drugs still 50–60% (Standing Committee on Health) [13]
• Report/Committee: Parliamentary Standing Committee report on the role of NPPA, August 2026 — no timeline for a permanent TMR framework [5]; Standing Committee on Health & Family Welfare, 175th–177th Reports [13]
• Law/Case: Para 19 (extraordinary powers) and Para 20(1) (annual increase limit) of DPCO 2013 [16][1]
• Comparison: WHO Guideline on Country Pharmaceutical Pricing Policies (2020) — a mark-up rate that falls as price rises, and published prices across the supply chain [14][15]
• Scheme: Ayushman Bharat PM-JAY — the insurance (pre-payment) route the Health Committee favours for the cost a price cap cannot reach

14. Mains Relevance

• GS-II: Issues relating to the development and management of the social sector and services relating to health; government policies and interventions.
• GS-III: Effects of liberalisation and industrial policy; government regulation of markets and pricing.
• Possible question stems: 1. "Trade Margin Rationalisation offers a middle path between price control and market freedom in pharmaceuticals." Critically examine this with reference to anti-cancer drugs. (GS-III, 15 marks) 2. Out-of-pocket expenditure on cancer care remains a major cause of medical impoverishment in India. Evaluate the role of drug-pricing regulation in addressing it. (GS-II, 10 marks) 3. Discuss the institutional framework for drug pricing in India. Why is a statutory, permanent TMR framework needed? (GS-II, 15 marks)

15. Related Topics to Study Next

• DPCO 2013 and NPPP 2012: the legal basis for all price regulation discussed here.
• NLEM 2022: decides which drugs are scheduled. Re-fixation saved about ₹3,788 crore a year [8].
• Trade margin cap on medical devices (stents, knee implants): the same method applied to devices.
• PM Bhartiya Janaushadhi Pariyojana: a supply-side route to cheaper generics that complements price caps.
• Ayushman Bharat PM-JAY: cancer packages and insurance cover, the demand-side counterpart.
• National Cancer Grid / NPCDCS: the public-health programme for cancer control.
• Customs duty exemption on cancer drugs (Union Budget): another fiscal lever on drug affordability.
• Compulsory licensing (Section 84, Patents Act): the IPR route to affordable cancer drugs (e.g., the Nexavar case).

16. NCERT Concepts to Revise

• Trade margin rationalisation (Economy): The core mechanism: capping supply-chain margin on non-scheduled drugs without fixing the manufacturer's own price.
• Drugs (Prices Control) Order, 2013 (Economy): The legal order behind all this, including Para 19 emergency powers and Para 20(1) annual increase limit.
• Scheduled and non-scheduled drugs (Economy): Explains why TMR is needed for non-scheduled drugs, which have no ceiling price, unlike scheduled NLEM drugs.
• National Pharmaceutical Pricing Authority (Polity): The regulator that issued the cap; a classic trap is its ministry and non-statutory origin.
• Out-of-pocket expenditure (Economy): Cancer care's high direct household spending is the social reason for the price cuts.
• National List of Essential Medicines (Economy): NLEM forms Schedule-I of DPCO and decides which drugs get ceiling prices instead of TMR.

17. Common Errors / Trap Areas

• Wrong ministry: NPPA is under the Ministry of Chemicals & Fertilizers, not MoHFW. DGHS (MoHFW) only constituted the expert committee [1].
• TMR vs ceiling price: TMR caps the supply-chain margin of non-scheduled drugs. Ceiling prices apply to scheduled (NLEM) drugs [1][6].
• 42 vs 137: 42 drugs was the 2019 pilot; 137 is the 2026 expansion [1][3].
• Formulations vs brands: 1,031 formulations had MRP cuts [1], while 543 brands were in the first published list, which keeps being updated [2]. The two counts measure different things.
• NPPA's legal status: NPPA was created by a Government Resolution (1997) and is not a statutory body under an Act [9].
• Dates: S.O. 5690(E) is dated 17 October 2026; the prices take effect on 9 November 2026 [1].